Identifying FLT3 Mutations in AML
Identifying FLT3 Mutations in Acute Myeloid Leukemia (AML) to Inform Clinical Decision-making – A Focus on Relapsed/Refractory Disease
No continuing education (CE) or continuing medical education (CME) credit can be provided for this presentation sponsored by Astellas Pharma US, Inc.
*Important note: Attendees are required to view the presented slides during the virtual program
To RSVP for this program – Please contact:
Kindly reply by March 23, 2021
In the RSVP, please include your name, contact information, organization, and specialty.